507435810 08/12/2022 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7482741

SUBMISSION TYPE:		NEW	NEW ASSIGNMENT					
NATURE OF CONVEYANCE:		ASSIC	ASSIGNMENT					
CONVEYING PARTY D	ΑΤΑ	·						
			Name				Execution Date]
MATTHEW JAMES CLEMENTE							02/24/2017	
ROBERT EUGENE TRZYBINSKI							02/24/2017	1
CAMBRIDGE DESIGN PARTNERSHIF							02/03/2017	
CAMBRIDGE DESIGN PARTNERSHIF			۰LTD				02/13/2017	
RECEIVING PARTY DA								
Name: Eli Lilly and Company							7	
Street Address:		Lilly Corporate Center				1		
Internal Address:		Patent Division				1		
City:	_	Indianapolis				-		
State/Country:		INDIANA				-		
Postal Code:	46285					-		
PROPERTY NUMBERS Total: 1 Property Type			Number					
Application Number:1646		16467314						
CORRESPONDENCE [ΔΤΑ							
Fax Number: (317)276-3861								
Correspondence will b	oe sent to	the e-mail	address first; if that is					
using a fax number, if	provideo			sen	t via	US M	ail.	
•			its@lilly.com ILLY AND COMPANY					
Address Line 1:		P. O. BOX 6288						
Address Line 1:		PATENT DIVISION						
Address Line 4:		INDIANAPOLIS, INDIANA 46206-6288						
ATTORNEY DOCKET N	UMBER:	X2099	93					
NAME OF SUBMITTER:			SHARON K MOMAN					
SIGNATURE:		/Shard	/Sharon K Moman/					
DATE SIGNED:			08/12/2022					
Total Attachments: 8								
source=P20993Assignme	entCleme	nte#page1.ti	f					

WHEREAS, I

MATTHEW JAMES CLEMENTE, Carmel, IN; Citizenship: US

am a co-inventor of an invention that is the subject of a patent application ("Application") which is entitled MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM, for filing:

in the United States Patent and Trademark Office on December 15, 2016 and accorded Serial Number 62/434684,

in the ______ on _____ on ______ and accorded Serial Number ______,

in the Spanish Patent Office as a European Application on _______ and accorded Serial Number ______,

as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office on and accorded Serial Number ______.

as an international application under the Patent Cooperation Treaty ("PCT"), with The State Intellectual Property Office (SIPO) of China acting as Receiving Office on ______ and accorded Serial Number

both of which claim the benefit of priority application Serial Number _____, filed ______.

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial number(s) and filing date(s) for the application when it is known.

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns (collectively "Lilly") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional

e Queene patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

<u>24 FEBDO17</u>

MATTHEW JAMÉS CLEMENTE

Date

WHEREAS, I

. Ý.

ROBERT EUGENE TRZYBINSKI, Westfield, IN; Citizenship: US

am a co-inventor of an invention that is the subject of a patent application ("Application") which is entitled MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM, for filing:

in the United States Patent and Trademark Office on December 15, 2016 and accorded Serial Number 62/434684,

[] in the	on
and accorded Serial Number	<u>*</u>

in the Spanish Patent Office as a European Application on ______ and accorded Serial Number ______,

as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office on and accorded Serial Number ______,

as an international application under the Patent Cooperation Treaty ("PCT"), with The State Intellectual Property Office (SIPO) of China acting as Receiving Office on _______and accorded Serial Number

both of which claim the benefit of priority application Serial Number _____, filed ______,

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial number(s) and filing date(s) for the application when it is known.

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns (collectively "Lilly") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional

> PATENT REEL: 060792 FRAME: 0834

patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

<u>24-Ee6-230</u>

ROBERT EUGENE TRZYBINSKI

WHEREAS, CAMBRIDGE DESIGN PARTNERSHIP LLP, an United Kingdom partnership having a place of business at Church Road, Toft, Cambridge, United Kingdom ("CDP LLP") has been assigned by JEREMY CLEMENTS his entire interest in each and every invention that is the subject of a patent application ("Application") which is entitled MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM, filed:

in the United States Patent and Trademark Office on December 15, 2016 and accorded Serial Number 62/434684,

in the Spanish Patent Office as a European Application on _________ and accorded Serial Number _______,

as an international application under the Patent Cooperation Treaty ("PCT"), with The State Intellectual Property Office (SIPO) of China acting as Receiving Office on ______ and accorded Serial Number

both of which claim the benefit of priority application Serial Number

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, CDP LLP hereby assigns to Eli Lilly and Company, its successors and assigns (collectively "Lilly") its entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which

such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by CDP LLP had this Assignment and sale to Lilly not been made.

For itself and for its successors and assigns, CDP LLP covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For itself and for its successors and assigns, CDP LLP further covenants and agrees with Lilly that upon request CDP LLP and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to it or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

IN WITNESS THEREOF CDP LLP has caused this assignment to be executed on the date indicated below.

CAMBRIDGE DESIGN PARTNERSHIP LLP

ひしつ Full Name:

Date: 3 FOR 2017

Capacity:

Accepted on behalf of ELI LILLY AND COMPANY

By:

eliabs K Full Nam Smercal Patent Chungel Capacity:



PATENT REEL: 060792 FRAME: 0837

WHEREAS, CAMBRIDGE DESIGN PARTNERSHIP LTD, an United Kingdom

corporation having a place of business at Church Road, Toft, Cambridge, United Kingdom

("CDP LTD") has been assigned by URI ELIEZER BARUCH, JAMES ANGUS

BOONZAIER, XORGE CASTRO, and JAMES ALEXANDER DAVIES their entire

interests in each and every invention that is the subject of a patent application ("Application")

which is entitled MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM, filed:

in the United States Patent and Trademark Office on December 15, 2016 and accorded Serial Number 62/434684.

in the Spanish Patent Office as a European Application on _______ and accorded Serial Number ______.

as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office on and accorded Serial Number ______,

as an international application under the Patent Cooperation Treaty ("PCT"), with The State Intellectual Property Office (SIPO) of China acting as Receiving Office on ______ and accorded Serial Number

both of which claim the benefit of priority application Serial Number _____, filed ______,

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, CDP LTD hereby assigns to Eli Lilly and Company, its successors and assigns (collectively "Lilly") its entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which

such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by CDP LTD had this Assignment and sale to Lilly not been made.

For itself and for its successors and assigns, CDP LTD covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For itself and for its successors and assigns, CDP LTD further covenants and agrees with Lilly that upon request CDP LTD and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to it or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

IN WITNESS THEREOF CDP LTD has caused this assignment to be executed on the date indicated below.

	CAMBRIDGE DESIGN PARTNERSHIP LTD By:
	Full Name: MATTHEW SCHUMANN
Date:	Capacity:DIRECTOR
	Accepted on behalf of
7Y2	By: Welly and COMPANY By: Welly Mr. W. Warn
	Full Name: Kright K. Norman
Date: February 3, 2017	Capacity: Vier President - Exneral Potent Courses

RECORDED: 08/12/2022